Scarica l'app Stockscreener
233.41
0.08%
-0.19
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Laboratories stock hits 52-week high at $236.67 - Investing.com India
Charles River Laboratories stock hits 52-week high at $236.67 By Investing.com - Investing.com Canada
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Laboratories International Inc (CRL) Shares Surge 4.3% -- What GF Score of 69 Tells Investors - GuruFocus
Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 - Moomoo
Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $226.79, Implies 1% Upside - TradingView
Charles River Laboratories highlights its role in drug development. Steady operations underpin the s - ad-hoc-news.de
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
ICON Stock and the CRO Trends Shaping Its Next Growth Phase - TradingView
Charles River Labs explores growth opportunities as a research partner. Business model supports long - ad-hoc-news.de
Charles River (CRL) Analyst Initiates 90-Day Catalyst Watch - GuruFocus
Charles River Laboratories International Stock Surges 27%, With A 9-Day Winning Spree - Trefis
The Endotoxin Testing ServicesCharles River Labs leans on high-throughput biosafety work - AD HOC NEWS
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 - Moomoo
Charles River Labs business profile and stock context - ad-hoc-news.de
Medpace Growth Trends Show How CRO Demand Is Shifting in 2026 - TradingView
Charles River Labs holds the line as investors await the next catalyst. - ad-hoc-news.de
Medpace Stock Outlook Turns on Backlog Quality and Cancellations - TradingView
Are Analyst Upgrades Signaling a Turning Point in Charles River’s (CRL) Biopharma Pipeline Narrative? - simplywall.st
Charles River Labs tops estimates, shares gain on guidance - Investing.com
CRLCharles River Laboratories International Inc Latest SEC Filings - Finviz
Charles River Shareholder Action Reminder - TMX Newsfile
Why is Morgan Stanley Bullish on Charles River Laboratories International, Inc. (CRL) as a Top Stock to Buy According to Ariel Investment? - Yahoo Finance
Charles River Labs stock holds steady on business context - AD HOC NEWS
Law firm investigates Charles River Labs officers for possible breach of fiduciary duties to shareholders - Pluang
Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Charles River Laboratories International Stock Rockets 27% With 8-Day Winning Streak - Trefis
Prestige Biopharma And Charles River Align On Biosimilar Development - insights.citeline.com
Charles River Laboratories International Non-Executive Director James Foster Sells 27% Of Holding - simplywall.st
CRL News | CHARLES RIVER LABORATORIES (NYSE:CRL) - ChartMill
3 Reasons to Avoid CRL and 1 Stock to Buy Instead - Yahoo Finance
Charles River Laboratories International Stock 7-Day Winning Spree: Stock Climbs 26% - Trefis
Top Charles River Laboratories International (CRL) Competitors 2026 - MarketBeat
Charles River Laboratories International (CRL) On Lilly TuneLab Deal And The Valuation Debate - simplywall.st
Charles River Labs director James C Foster reduces stake by $16.8m - Investing.com
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Form 4 Charles River Laboratories Intl For: 1 July By Investing.com - Investing.com Canada
Director at Charles River (NYSE: CRL) sells 75K shares under 10b5-1 plan - Stock Titan
LH or CRL: Which Is the Better Value Stock Right Now? - Yahoo Finance
How is Charles River Laboratories’ stock performance compared to other health care stocks? - MSN
Charles River Laboratories updates operations strategy as research demand evolves - AD HOC NEWS
Charles River Laboratories stock hits 52-week high at 229.18 USD - Investing.com Nigeria
Charles River Laboratories stock hits 52-week high at 229.18 USD By Investing.com - Investing.com India
Is This the Right Time to Hold CRL Stock in Your Portfolio? - TradingView
Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating - Moomoo
Argus raises Charles River Labs stock price target on M&A strategy - Investing.com South Africa
Charles River Deadline Alert - TMX Newsfile
Charles River Laboratories consensus steadies, shares trade in a crowded life-science field - AD HOC NEWS
A Look at Charles River Laboratories International Inc (CRL) Aft - GuruFocus
CRL (CRL) Form 144: 75,000-share resale via UBS Financial Services - Stock Titan
Is Charles River Laboratories International, Inc. (CRL) A Good Stock To Buy Now? - Insider Monkey
Charles River Laboratories International Inc (CRL)'s Uncertain F - GuruFocus
The Decentralized Safety Assessments from Charles River Laboratories International Inc.toxicology - AD HOC NEWS
Charles River Laboratories strategy focus, S&P 500 health stock in contract research - AD HOC NEWS
The Safety Assessment Services from Charles River Laboratoriesa quiet backbone of drug developmen - Ad-hoc-news.de
Price to earnings forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView
Charles River Laboratories lands Morgan Stanley upgrade, shares in analyst focus - Ad-hoc-news.de
0.29%
0.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):